LONDON – Circassia Ltd. is looking for shareholders’ backing for a Phase III trial of its house dust mite allergy treatment after reporting positive results in a Phase II study, with subjects who received the most effective dose showing a significant reduction in symptoms of allergic rhinitis at one year.